Get started
Author

Kristin Goddard

Observed names: Goddard, Kristin, K. Goddard, Kristin S. Goddard
Observed institutions: Intermountain Healthcare, University of North Carolina at Chapel Hill, Centers for Disease Control and Prevention, Regenstrief Institute, Kaiser Permanente, Columbia University Irving Medical Center, Kaiser Permanente Oakland Medical Center, Centers for Disease Control and Prevention, Kaiser Permanente Center for Health Research, Baylor Scott & White Health, Center for Surveillance, Epidemiology, and Laboratory Services, Indiana University School of Medicine, Kaiser Permanente Bernard J. Tyson School of Medicine, Kaiser Permanente Northern California, HealthPartners
ORCID: 0000-0001-8804-2958
Observed ORCID: 0000-0001-8804-2958
OpenAlex ID: A5088198148
Surveillance for Adverse Events After COVID-19 mRNA Vaccination
2021 · Nicola P. Klein, Ned Lewis, et al. · JAMA · 626
PDF
Effectiveness of Covid-19 Vaccines in Ambulatory and Inpatient Care Settings
2021 · Mark G. Thompson, Edward Stenehjem, et al. · New England Journal of Medicine · 468
Waning 2-Dose and 3-Dose Effectiveness of mRNA Vaccines Against COVID-19–Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance — VISION Network, 10 States, August 2021–January 2022
2022 · Jill M. Ferdinands, Suchitra Rao, et al. · MMWR Morbidity and Mortality Weekly Report · 435
PDF
Effectiveness of a Third Dose of mRNA Vaccines Against COVID-19–Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance — VISION Network, 10 States, August 2021–January 2022
2022 · Mark G. Thompson, Karthik Natarajan, et al. · MMWR Morbidity and Mortality Weekly Report · 397
PDF
Waning of vaccine effectiveness against moderate and severe covid-19 among adults in the US from the VISION network: test negative, case-control study
2022 · Jill M Ferdinands, Suchitra Rao, et al. · BMJ · 185
PDF
Influenza Vaccine Effectiveness in Preventing Influenza-associated Hospitalizations During Pregnancy: A Multi-country Retrospective Test Negative Design Study, 2010–2016
2018 · Mark G Thompson, Jeffrey C Kwong, et al. · Clinical Infectious Diseases · 184
Effectiveness of COVID-19 Pfizer-BioNTech BNT162b2 mRNA Vaccination in Preventing COVID-19–Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Nonimmunocompromised Children and Adolescents Aged 5–17 Years — VISION Network, 10 States, April 2021–January 2022
2022 · Nicola P. Klein, Melissa S. Stockwell, et al. · MMWR Morbidity and Mortality Weekly Report · 179
PDF
Effectiveness of 2-Dose Vaccination with mRNA COVID-19 Vaccines Against COVID-19–Associated Hospitalizations Among Immunocompromised Adults — Nine States, January–September 2021
2021 · Peter J. Embi, Matthew E. Levy, et al. · MMWR Morbidity and Mortality Weekly Report · 172
Incidence of Guillain-Barré Syndrome After COVID-19 Vaccination in the Vaccine Safety Datalink
2022 · Kayla E. Hanson, Kristin Goddard, et al. · JAMA Network Open · 159
PDF
Respiratory syncytial virus (RSV) vaccine effectiveness against RSV-associated hospitalisations and emergency department encounters among adults aged 60 years and older in the USA, October, 2023, to March, 2024: a test-negative design analysis
2024 · Amanda B Payne, Janet A Watts, et al. · The Lancet · 135
Overdose Education and Naloxone for Patients Prescribed Opioids in Primary Care: A Qualitative Study of Primary Care Staff
2015 · Ingrid A. Binswanger, Stephen Koester, et al. · Journal of General Internal Medicine · 128
PDF
Effectiveness of 2, 3, and 4 COVID-19 mRNA Vaccine Doses Among Immunocompetent Adults During Periods when SARS-CoV-2 Omicron BA.1 and BA.2/BA.2.12.1 Sublineages Predominated — VISION Network, 10 States, December 2021–June 2022
2022 · Ruth Link-Gelles, Matthew E. Levy, et al. · MMWR Morbidity and Mortality Weekly Report · 126
PDF
Early Estimates of Bivalent mRNA Vaccine Effectiveness in Preventing COVID-19–Associated Emergency Department or Urgent Care Encounters and Hospitalizations Among Immunocompetent Adults — VISION Network, Nine States, September–November 2022
2022 · Mark W. Tenforde, Zachary A. Weber, et al. · MMWR Morbidity and Mortality Weekly Report · 104
PDF
Estimates of Bivalent mRNA Vaccine Durability in Preventing COVID-19–Associated Hospitalization and Critical Illness Among Adults with and Without Immunocompromising Conditions — VISION Network, September 2022–April 2023
2023 · Ruth Link-Gelles, Zachary A. Weber, et al. · MMWR Morbidity and Mortality Weekly Report · 95
PDF
Laboratory-Confirmed COVID-19 Among Adults Hospitalized with COVID-19–Like Illness with Infection-Induced or mRNA Vaccine-Induced SARS-CoV-2 Immunity — Nine States, January–September 2021
2021 · Catherine H. Bozio, Shaun J. Grannis, et al. · MMWR Morbidity and Mortality Weekly Report · 91
Interim Estimates of 2023–24 Seasonal Influenza Vaccine Effectiveness — United States
2024 · Aaron M. Frutos, Ashley M. Price, et al. · MMWR Morbidity and Mortality Weekly Report · 90
PDF
Estimation of COVID-19 mRNA Vaccine Effectiveness and COVID-19 Illness and Severity by Vaccination Status During Omicron BA.4 and BA.5 Sublineage Periods
2023 · Ruth Link-Gelles, Matthew E. Levy, et al. · JAMA Network Open · 83
PDF
Effectiveness of COVID-19 mRNA Vaccines Against COVID-19–Associated Hospitalizations Among Immunocompromised Adults During SARS-CoV-2 Omicron Predominance — VISION Network, 10 States, December 2021—August 2022
2022 · Amadea Britton, Peter J. Embi, et al. · MMWR Morbidity and Mortality Weekly Report · 82
Acute Demyelinating Events Following Vaccines: A Case-Centered Analysis
2016 · Roger Baxter, Edwin Lewis, et al. · Clinical Infectious Diseases · 80
PDF
Interim Effectiveness of Updated 2023–2024 (Monovalent XBB.1.5) COVID-19 Vaccines Against COVID-19–Associated Emergency Department and Urgent Care Encounters and Hospitalization Among Immunocompetent Adults Aged ≥18 Years — VISION and IVY Networks, September 2023–January 2024
2024 · Jennifer DeCuir, Amanda B. Payne, et al. · MMWR Morbidity and Mortality Weekly Report · 72
PDF
Risk of Myocarditis and Pericarditis Following BNT162b2 and mRNA-1273 COVID-19 Vaccination
2022 · Kristin Goddard, Ned Lewis, et al. · Vaccine · 70
PDF
Acellular Pertussis Vaccine Effectiveness Over Time
2019 · Ousseny Zerbo, Joan Bartlett, et al. · PEDIATRICS · 69
Safety of COVID-19 Vaccination in United States Children Ages 5 to 11 Years
2022 · Anne M. Hause, David K. Shay, et al. · PEDIATRICS · 65
Incidence of Myocarditis/Pericarditis Following mRNA COVID-19 Vaccination Among Children and Younger Adults in the United States
2022 · Kristin Goddard, Kayla E. Hanson, et al. · Annals of Internal Medicine · 61
Estimation of COVID-19 mRNA Vaccine Effectiveness Against Medically Attended COVID-19 in Pregnancy During Periods of Delta and Omicron Variant Predominance in the United States
2022 · Stephanie J. Schrag, Jennifer R. Verani, et al. · JAMA Network Open · 61
PDF
Works count: 115
Citation count: 5,426
H-index: 38
I10-index: 63
Year
Topic
Type